Company intelligence / Profile preview

Cardurion Pharmaceuticals

Burlington, Massachusetts, USAcardurion.com ↗

Ownership: Private
Employees: ~100
Development stage: Phase 2

Overview

Cardurion has presented positive clinical data from CARDINAL-HF, the first Phase 2 proof-of-concept clinical trial of a PDE9 inhibitor in patients with heart failure. Based on these results, the company has launched two Phase 2 clinical trials in 640 patients, including a dose-ranging trial in patients with HFrEF and a proof-of-concept trial in patients with HFpEF. The company is also conducting a Phase 2 trial for its CaMKII inhibitor in CPVT. Data readouts for these trials are anticipated in 2026.

Therapeutic areas: Cardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

6 assets

CRD-4730

5 more assets in the full pipeline.

Request access →

Partnerships

foundational partnerships with key strategics

Beyond the preview

Go deeper on Cardurion Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardurion Pharmaceuticals.

Explore the full profile